Spero Therapeutics, Inc. (SPRO)
Largest Insider Buys in Sector
SPRO Stock Price History Chart
SPRO Stock Performance
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, …
Insider Activity of Spero Therapeutics, Inc.
Over the last 12 months, insiders at Spero Therapeutics, Inc. have bought $0 and sold $375,379 worth of Spero Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Spero Therapeutics, Inc. have bought $11.07M and sold $3.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,727 shares for transaction amount of $207,971 was made by Aquilo Capital, L.P. () on 2022‑04‑26.
List of Insider Buy and Sell Transactions, Spero Therapeutics, Inc.
| 2024-08-27 | Sale | CEO & President | 2,757 0.005% | $1.35 | $3,722 | -5.07% | ||
| 2024-08-27 | Sale | director | 5,912 0.0107% | $1.35 | $7,981 | -5.07% | ||
| 2024-08-27 | Sale | Chief Operating Officer | 2,213 0.004% | $1.35 | $2,988 | -5.07% | ||
| 2024-08-05 | Sale | CEO and President | 17,641 0.0319% | $1.31 | $23,110 | -2.24% | ||
| 2024-08-02 | Sale | CEO and President | 14,800 0.0276% | $1.32 | $19,536 | 0.00% | ||
| 2024-02-05 | Sale | CEO and President | 45,093 0.0786% | $1.45 | $65,385 | -0.69% | ||
| 2024-02-02 | Sale | CEO and President | 30,901 0.0509% | $1.37 | $42,334 | -2.05% | ||
| 2024-02-02 | Sale | Chief Medical Officer | 28,075 0.0462% | $1.37 | $38,463 | -2.05% | ||
| 2024-02-02 | Sale | director | 63,795 0.105% | $1.37 | $87,399 | -2.05% | ||
| 2024-02-02 | Sale | Chief Operating Officer | 30,971 0.0506% | $1.36 | $42,121 | -2.05% | ||
| 2024-02-02 | Sale | Chief Legal Officer | 30,906 0.0509% | $1.37 | $42,341 | -2.05% | ||
| 2023-09-13 | Sale | Chief Medical Officer | 39,496 0.0732% | $1.27 | $50,160 | +10.08% | ||
| 2023-08-29 | Sale | CEO and President | 4,163 0.0075% | $1.30 | $5,412 | +3.65% | ||
| 2023-08-28 | Sale | director | 9,040 0.0172% | $1.26 | $11,390 | +12.70% | ||
| 2023-08-28 | Sale | CEO and President | 1,854 0.0035% | $1.26 | $2,336 | +12.70% | ||
| 2023-08-28 | Sale | Chief Development Officer | 1,854 0.0035% | $1.26 | $2,336 | +12.70% | ||
| 2023-08-28 | Sale | Chief Legal Officer | 1,854 0.0035% | $1.26 | $2,336 | +12.70% | ||
| 2023-02-03 | Sale | CEO and President | 12,286 0.0223% | $1.81 | $22,238 | -23.68% | ||
| 2023-02-02 | Sale | Chief Operating Officer | 3,394 0.0066% | $1.86 | $6,313 | -20.77% | ||
| 2023-02-02 | Sale | Chief Legal Officer | 3,394 0.0066% | $1.86 | $6,313 | -20.77% |
Insider Historical Profitability
| Aquilo Capital, L.P. | 5321231 9.8452% | $1.32 | 3 | 0 | ||
| Aquilo Capital Management, LLC | 10 percent owner | 5207796 9.6353% | $1.32 | 21 | 11 | |
| FORMELA JEAN FRANCOIS | director | 2408128 4.4554% | $1.32 | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1934006 3.5782% | $1.32 | 2 | 0 | <0.0001% |
| Goyal Vikas | director | 1854006 3.4302% | $1.32 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Anson Funds Management Lp | $6.45M | 6.95 | 3.75M | -12.73% | -$941,268.28 | 0.41 | |
| The Vanguard Group | $2.84M | 3.06 | 1.65M | +0.59% | +$16,641.00 | <0.0001 | |
| Alphabet | $1.53M | 1.65 | 889,979 | 0% | +$0 | 0.01 | |
| Murchinson Ltd | $1.5M | 1.62 | 873,910 | +1.3% | +$19,281.20 | 0.17 | |
| Renaissance Technologies | $1.47M | 1.58 | 854,460 | +56.08% | +$528,149.53 | <0.01 |